Physician profile

Andrea M Pezzella

Gynecology · West Columbia, SC

NPI 1730157058

$99,113.83

in general payments reported to CMS, 2019-2025

35 companies · $7,525 in 2025

The $7,525 reported for 2025 was more than what 94% of Gynecology providers received nationally (typical 2025 total: $162).

See the full distribution for Gynecology

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$42,426.45
Food and Beverage$7,853.43
Travel and Lodging$3,722.75
Honoraria$280.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Axonics, INC. $48,535.96 2020-2024 Axonics, Bulkamid
Medtronic USA, INC. $13,933.14 2019-2020
Abbvie INC. $8,711.52 2019-2025
Femselect INC. $7,109.30 2022-2025 Enplace
Contura, INC. $4,350.00 2020
Medtronic, INC. $3,593.05 2020-2025 Interstim, Altaviva, Nuro
Coloplast Corp $3,472.36 2019-2025 Altis, Speedicath, Restorelle
Escala Medical INC. $2,641.45 2024-2025
Bluewind Medical $1,649.83 2020-2024
Allergan, INC. $1,468.88 2019-2022
Boston Scientific Corporation $761.44 2024-2025 Axonics, Avvigo Guidance System, Solyx Sis System
Astellas Pharma US INC $601.56 2019-2024 Veozah, Myrbetriq
Sumitomo Pharma America, INC. $405.01 2023-2025 Gemtesa
Pfizer INC. $225.51 2019-2022
Laborie Medical Technologies Corp. $212.28 2019-2024 Kiwi Procup
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Antares Pharma, INC. $182.33 2021-2022
Urovant Sciences INC $180.40 2021-2022
Duchesnay USA Incorporated $143.02 2019
Valencia Technologies Corporation $135.18 2023-2024 Ecoin Device Kit
Coopersurgical, INC. $132.80 2019-2025 Ally II Ups
Caldera Medical, INC $127.75 2025
Hologic Sales and Service, LLC $116.78 2020-2024 Thinprep 2000 Processor, Aptima
Therapeuticsmd, INC. $65.21 2019-2020
Abc Home Medical Supply, INC. $56.29 2022-2024
180 Medical, INC. $48.57 2019-2023 Gentlecath Glide
Millicent US INC $43.76 2024-2025 Intrarosa, Femring
Mission Pharmacal Company $42.44 2019-2021
Amag Pharmaceuticals, INC. $37.83 2019
Intuitive Surgical, INC. $30.20 2020-2023 Da Vinci Surgical System
Bayer Healthcare Pharmaceuticals INC. $25.74 2019
Merck Sharp & Dohme LLC $16.34 2019
Virtus Pharmaceuticals LLC $16.04 2021
Ferring Pharmaceuticals INC. $15.38 2019
Hollister Incorporated $14.43 2021
Organon LLC $12.05 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$3,330.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Andrea M Pezzella

$99,113.83

in general payments reported 2019-2025

Years
2019-2025
Top company
Axonics, INC.
Context
The $7,525 reported for 2025 was more than what 94% of Gynecology providers received nationally (typical 2025 total: $162).

https://glasscript.com/doctor/78902/andrea-m-pezzella

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.